Q1 2024 Vistin Pharma ASA Earnings Call Transcript
Welcome all to this the first quarter 2024 presentation. And we will now start by going through the highlights of the quarter.
The revenue of the first quarter ended at NOK104 million versus NOK101 million in the first quarter of 2023. The 11% increased sales volume compared to the same quarter last year has resulted in higher revenue. We have had an unplanned maintenance repair on the Line 2 in the quarter, which has resulted in a lower than planned production and sales volume. The EBITDA of the first quarter ended at NOK20 million versus NOK14 million in the first quarter 2023, an increase of 45% if we compare this quarter with the first quarter of 2023.
The EBITDA was positively affected by increased sales volume and the product mix and the EBITDA was negatively affected by a onetime inventory adjustment of NOK7 million. After the unplanned maintenance and repair on Line 2 in the first quarter, the line has been producing according to plan from fiscal week 14. Fiscal week 14, that's the first week of April. So Line 2 was under repair for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
